Thomas Catinazzo Relay Therapeutics, Inc. (RLAY) insider trading activity

Thomas Catinazzo is Chief Financial Officer of Relay Therapeutics, Inc.. Currently has a direct ownership of 355,376 shares of RLAY, which is worth approximately $1.35 Million. The most recent transaction as insider was on Jan 30, 2023, when has been sold 864 shares (Common Stock) at a price of $21.56 per share, resulting in proceeds of $18,627. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 355K

5.12% 3M change

7.55% 12M change

Total Value Held $1.35 Million

Thomas Catinazzo Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 30 2023	SELL Open market or private sale	$18,627 $21.56 p/Share	864 Reduced 0.57%	150,482 Common Stock
Jan 17 2023	BUY Grant, award, or other acquisition	-	101,115 Added 40.05%	151,346 Common Stock
Dec 27 2022	SELL Open market or private sale	$6,448 $14.49 p/Share	445 Reduced 0.88%	50,231 Common Stock
Oct 28 2022	SELL Open market or private sale	$23,672 $21.54 p/Share	1,099 Reduced 2.12%	50,676 Common Stock
Sep 27 2022	SELL Open market or private sale	$10,069 $22.73 p/Share	443 Reduced 0.85%	51,775 Common Stock
Sep 08 2022	SELL Open market or private sale	$787,710 $30.0 p/Share	26,257 Reduced 33.46%	52,218 Common Stock
Sep 08 2022	BUY Exercise of conversion of derivative security	$108,179 $4.12 p/Share	26,257 Added 25.07%	78,475 Common Stock
Jul 28 2022	SELL Open market or private sale	$15,605 $21.26 p/Share	734 Reduced 1.39%	52,218 Common Stock
Jun 27 2022	SELL Open market or private sale	$6,093 $20.31 p/Share	300 Reduced 0.56%	52,952 Common Stock
Apr 28 2022	SELL Open market or private sale	$18,538 $25.57 p/Share	725 Reduced 1.34%	53,252 Common Stock
Mar 29 2022	SELL Open market or private sale	$8,423 $29.87 p/Share	282 Reduced 0.52%	53,977 Common Stock
Mar 24 2022	SELL Open market or private sale	$398,580 $30.0 p/Share	13,286 Reduced 19.67%	54,259 Common Stock
Mar 24 2022	BUY Exercise of conversion of derivative security	$54,738 $4.12 p/Share	13,286 Added 16.44%	67,545 Common Stock
Jan 27 2022	BUY Grant, award, or other acquisition	-	39,270 Added 41.99%	54,259 Common Stock
Dec 27 2021	SELL Open market or private sale	$9,764 $33.1 p/Share	295 Reduced 1.93%	14,989 Common Stock
Nov 15 2021	SELL Open market or private sale	$796,500 $35.4 p/Share	22,500 Reduced 59.55%	15,284 Common Stock
Nov 15 2021	BUY Exercise of conversion of derivative security	$92,700 $4.12 p/Share	22,500 Added 37.32%	37,784 Common Stock
Sep 27 2021	SELL Open market or private sale	$10,803 $36.87 p/Share	293 Reduced 1.88%	15,284 Common Stock
Sep 13 2021	SELL Open market or private sale	$787,500 $35.0 p/Share	22,500 Reduced 59.09%	15,577 Common Stock
Sep 13 2021	BUY Exercise of conversion of derivative security	$92,700 $4.12 p/Share	22,500 Added 37.14%	38,077 Common Stock
Jun 28 2021	SELL Open market or private sale	$10,492 $35.81 p/Share	293 Reduced 1.85%	15,577 Common Stock
Jun 07 2021	SELL Open market or private sale	$787,500 $35.0 p/Share	22,500 Reduced 58.64%	15,870 Common Stock
Jun 07 2021	BUY Exercise of conversion of derivative security	$92,700 $4.12 p/Share	22,500 Added 36.96%	38,370 Common Stock
Mar 30 2021	SELL Open market or private sale	$787,500 $35.0 p/Share	22,500 Reduced 100.0%	0 Common Stock
Mar 30 2021	BUY Exercise of conversion of derivative security	$92,700 $4.12 p/Share	22,500 Added 50.0%	22,500 Common Stock

Thomas Catinazzo

Chief Financial Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RLAY shares.

Notify only if

Value

Insider Trading

Get notified when an Relay Therapeutics, Inc. insider buys or sells RLAY shares.

Notify only if

Operation

Value

Type

News

Receive news related to Relay Therapeutics, Inc.

Track Activities on RLAY

Account